Long-term, Head-to-Head Study Showed SPIRIVA HandiHaler (tiotropium bromide inhalation powder) Significantly Prolonged Time to First Moderate or Severe COPD Exacerbation versus Salmeterol HFA-MDI The ...
Major League Baseball’s annual All-Star Game last night featured new DTC spots for Spiriva HandiHaler, an inhaler indicated for chronic bronchitis and emphysema. The television spots were created by ...
Boehringer Ingelheim announced that Spiriva Respimat (tiotropium bromide) is now available for the long-term maintenance treatment of asthma in patients ages ≥12 years. Boehringer Ingelheim announced ...
INGELHEIM AM RHEIN, Germany & NEW YORK, N.Y., USA--(BUSINESS WIRE)--Results of the one-year Prevention Of Exacerbations with Tiotropium in COPD (POET-COPD ®) study, published today by the New England ...
DUBLIN--(BUSINESS WIRE)--The "Spiriva" report has been added to ResearchAndMarkets.com's offering. Spiriva (tiotropium; Boehringer Ingelheim) is a long-acting muscarinic antagonist (LAMA) approved for ...
RIDGEFIELD, Conn. & NEW YORK--(BUSINESS WIRE)--The U.S. Food and Drug Administration (FDA) Pulmonary-Allergy Drugs Advisory Committee voted 11 to 1 that clinical data included in a supplemental new ...
Post hoc analyses of some Phase 3 placebo-controlled studies showed that adding Spiriva Respimat improved peak FEV1(0-3h) and trough FEV1 across a range of baseline IgE levels and eosinophil counts.
Committee Voted Based on Clinical Data from Eight Efficacy Trials RIDGEFIELD, Conn., Aug. 14, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results